Another case of vaccine-induced thrombosis reported in Canada
AstraZeneca's scandalous vaccine is back at the top of the debate.
On Saturday April 17, Alberta Chief Medical Officer of Health Dr. Dina Hinshaw confirmed that a case of thrombosis related to the AstraZeneca vaccine has been reported in the region. This is the second case in Canada — just 5 days earlier, thrombosis was detected in a patient in Quebec. Before that, Canada's National Advisory Committee did not recommend the use of AstraZeneca for people under 55 years old, and the first cases of thrombosis were recorded in Europe, after which several countries rejected the vaccine.
A case reported in Alberta presents with a clotting disorder called vaccine-induced immune thrombocytopenia (VITT).
According to Dr. Hinshaw, it happened to a man in his 60s. He is now on the mend but details of the patient are not being released so as not to breach confidentiality. Hinshaw added that she continues to recommend AstraZeneca to people over the age of 55 and that all people get vaccinated at the earliest opportunity.
Hinshaw emphasized that the side effect in the form of thrombosis is extremely rare — 2 cases per 700,000 doses administered in Canada by AstraZeneca. She reminds us that the vaccine helps prevent the much higher risks associated with COVID-19.
Globally, the incidence of VITT is estimated to be about 1 case per 100,000-250,000 doses of vaccine. In Alberta, in residents over 55 years of age, the risk of death from COVID-19 is estimated to be 1 case per 200 confirmed infections.
Another problematic vaccine could be Johnson & Johnson, after which several cases of thrombosis were discovered in the US. No vaccine batches have yet arrived in Canada.
